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Mantle cell lymphoma (MCL) is an aggressive B-cell
malignancy with a reported median overall survival (OS)
of 3–5 years [1]. Most patients relapse after first-line therapy
and have a poor prognosis [1]. Regulatory approval of
ibrutinib has provided a much needed therapeutic option for
patients with relapsed or refractory (R/R) MCL [2], with
ibrutinib becoming a preferred standard of care in current
guidelines [3, 4]. The randomized, open-label phase 3 RAY
study (NCT01646021) was key in confirming the efficacy
and safety of ibrutinib, with ibrutinib (N= 139) showing
significantly improved progression-free survival (PFS) versus
temsirolimus (N= 141) (primary analysis [20-month follow-
up]: 14.6 vs. 6.2 months, hazard ratio [HR] 0.43, 95% con-
fidence interval [CI]: 0.32–0.58) [5]. Here, we report exten-
ded follow-up data from the final analysis of the RAY study.
At this final analysis, after an almost doubled median
study follow-up of 38.7 months, 33 patients (24%) in the
ibrutinib group and no patients in the temsirolimus group
remained on initially randomized treatment. Crossover to
ibrutinib from the temsirolimus group was permitted for
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patients who had confirmed disease progression. Fifty-five
patients in the temsirolimus group (39%) received sub-
sequent ibrutinib (42 were included in the formal study
crossover; 13 received ibrutinib outside of the study). Dis-
ease progression or relapse was the most common reason
for discontinuing treatment for both groups (ibrutinib, 78
patients [56%]; temsirolimus, 66 patients [47%]). Fewer
patients in the ibrutinib group (12 [9%]) than in the tem-
sirolimus group (39 [28%]) discontinued treatment due to
adverse events (AEs); eight patients in each arm
Fig. 1 Efficacy end points in 3-year follow-up in RAY study: a
Progression-free survival for ibrutinib and temsirolimus by prior line
of therapy; b Overall survival for ibrutinib and temsirolimus by prior
line of therapy; c Duration of clinical response by prior line of therapy
in patients randomized to ibrutinib; d Time to second progression or
death for ibrutinib and temsirolimus
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discontinued due to death. Other reasons for discontinuation
included refusing further treatment. Median duration of
exposure was longer for ibrutinib than temsirolimus (ibru-
tinib, 14.4 months; temsirolimus, 3.0 months), as in the
primary analysis.
Efficacy assessments at primary analysis by the Inde-
pendent Review Committee showed high concordance with
investigator assessment; at final analysis, all efficacy ana-
lyses were based on investigator assessment. With additional
follow-up, median PFS remained significantly longer for
ibrutinib than temsirolimus (15.6 vs. 6.2 months; HR 0.45
[95% CI 0.35–0.60]; P < 0.0001); consistent with the results
of the primary analysis [5]. An exploratory post hoc analysis
evaluated PFS by number of prior lines of therapy received
(ibrutinib, 57 [41%] 1 prior line and 82 [59%] >1 prior line;
temsirolimus, 50 [35%] 1 prior line and 91 [65%] >1 prior
line). Median PFS for ibrutinib was significantly longer than
temsirolimus regardless of the number of prior lines of
treatment, and the difference in median PFS between
ibrutinib-treated and temsirolimus-treated patients was
greatest in those who received 1 prior line of therapy versus
>1 (1 prior line, 25.4 vs. 6.2 months, respectively, HR 0.40
[95% CI 0.25–0.64] >1 prior line, 12.1 vs. 6.0 months
respectively, HR 0.53 [95% CI 0.38–0.73]; Fig. 1a).
At the time of final analysis, 77 patients (55%) in the
ibrutinib group and 83 (59%) in the temsirolimus group had
died, with a trend toward improved OS in the patients
randomized to receive ibrutinib versus temsirolimus (30.3
vs. 23.5 months, respectively; HR 0.74 [95% CI 0.54–1.02];
P= 0.0621). Median OS was longer for ibrutinib than
temsirolimus regardless of the extent of prior treatment.
However, similar to PFS, a more pronounced OS difference
was observed between ibrutinib and temsirolimus treatment
in those patients who had received 1 prior line of therapy (1
prior line, 42.1 vs. 27.0 months, respectively, HR 0.74
[95% CI 0.43–1.30]; >1 prior line, 22.1 vs. 17.0 months
respectively, HR 0.86 [95% CI 0.59–1.25]; Fig. 1b).
Overall response rate (ORR) in the final analysis was
consistent with the primary analysis (77% for ibrutinib vs.
47% for temsirolimus; odds ratio 4.27 [95% CI 2.47–7.39];
P < 0.0001), with a higher proportion of patients achieving a
complete response (CR) with ibrutinib (23%) than with
temsirolimus (3%). ORR results for ibrutinib were similar
regardless of extent of prior treatment (75 vs. 78% for 1 prior
line and >1 prior line, respectively). However, the CR rate
was two-fold higher in patients treated with ibrutinib who
received 1 prior line of therapy than those who received >1
prior line: 33 and 16%, respectively. Overall median dura-
tion of response (DOR) was 23.1 months (95% CI
16.2–28.1) with ibrutinib and 6.3 months (95% CI 4.7–8.6)
with temsirolimus. Patients who achieved a CR on ibrutinib
had a longer median DOR than patients who achieved a
partial response (PR) (35.6 [N= 32] vs. 12.1 months [n=
75]; Fig. 1c). While DOR for patients achieving CR with
ibrutinib remained consistent regardless of the extent of prior
treatment (35.6 [N= 19] vs 32.2 months [N= 13] for 1 and
>1 prior line of therapy, respectively), the DOR for patients
achieving PR decreased with increasing lines of prior ther-
apy (22.3 [N= 24] vs. 10.0 months [N= 51], respectively,
for those who had received 1 vs. >1 prior line of therapy).
Therefore, DOR for complete responders with only 1 prior
line was more than three times longer than for partial
responders with >1 prior line of therapy.
Consistent with the primary analysis, the most common
treatment-emergent AEs (TEAEs) of any grade were diar-
rhea (33%), fatigue (24%), and cough (23%) in the ibrutinib
group, and thrombocytopenia (56%), anemia (44%), and
diarrhea (31%) in the temsirolimus group. Despite longer
treatment exposure in the ibrutinib group versus the tem-
sirolimus group, the frequency of grade ≥3 TEAEs (75 vs.
87%), serious AEs of any grade (57 vs. 60%) and AEs
leading to discontinuation (17 vs. 32%) were lower in the
ibrutinib group than in the temsirolimus group, respectively.
The most common grade ≥3 TEAEs for both groups were
hematological in nature and were less frequently reported in
the ibrutinib group than the temsirolimus group, respec-
tively: neutropenia (13 vs. 17%), thrombocytopenia (9 vs.
43%) and anemia (9 vs. 20%) (Table 1). The rate of any
grade bleeding was 40 and 33% in the ibrutinib and tem-
sirolimus groups, respectively. The rate of grade ≥3 bleeding
was 9% in the ibrutinib group and 5% in the temsirolimus
group, with exposure-adjusted rates being lower in the
ibrutinib group (0.455 events per 100 patient-months) versus
Table 1 Treatment-emergent adverse events (AEs) in ≥20% of
patients in either treatment arm
Safety population Ibrutinib
(N= 139)
Temsirolimus
(N= 139)
AE (%) Any
grade
Grade ≥3 Any grade Grade ≥3
Hematological
Thrombocytopenia 18.0 9.4 56.1 43.2
Anemia 19.4 8.6 43.9 20.1
Neutropenia 15.8 12.9 26.6 17.3
Non-hematological
Diarrhea 33.1 3.6 30.9 4.3
Fatigue 23.7 5.0 28.8 7.2
Cough 23.0 0.7 22.3 0.0
Upper respiratory
tract infection
20.1 2.2 11.5 0.7
Pyrexia 18.7 0.7 20.9 2.2
Nausea 14.4 0.0 21.6 0.0
Peripheral edema 13.7 0.0 23.7 2.2
Epistaxis 9.4 0.7 23.7 1.4
Stomatitis 2.9 0.0 20.9 3.6
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the temsirolimus group (0.785 events per 100 patient-
months). A higher rate of grade ≥3 atrial fibrillation was
observed in the ibrutinib group (5%) versus the temsirolimus
group (1%); exposure-adjusted rates were similar for both
groups (0.272 events per 100 patient-months for ibrutinib;
0.221 events per 100 patient-months for temsirolimus).
With longer-term follow-up, the data support a sustained
clinical benefit of ibrutinib. Median time to next treatment
(TTNT) was longer for patients in the ibrutinib group versus
the temsirolimus group (31. 8 vs. 11.6 months; HR 0.33
[95% CI 0.24–0.46]; P < 0.0001). Moreover, median time
from randomization to progression or death after subsequent
therapy (PFS2) was longer for ibrutinib than temsirolimus
(26.2 vs. 15.4 months; HR 0.67 [95% CI 0.50–0.90];
P= 0.0079; Fig. 1d).
Nearly half (N= 29; 46%) of 63 patients randomized
to ibrutinib who received subsequent anticancer therapy
on study were treated with rituximab-based chemotherapy.
In these 29 patients, following treatment with ibrutinib,
the ORR with rituximab-based chemotherapy was 41%
(24% CR [N= 7]; 17% PR [N= 5]); response was missing
or not evaluable in 11 patients. Fifteen of these 29 patients
were treated specifically with bendamustine-rituximab
following ibrutinib (ORR 53%; 40% CR [N= 6], 13% PR
[N= 2]); response was missing or not evaluable in six
patients.
In conclusion, longer-term follow-up from the final ana-
lysis of the RAY study supports the initial report, demon-
strating significant improvement in ORR and PFS with
ibrutinib over temsirolimus in patients with R/R MCL. At the
final analysis, OS showed a trend in favor of ibrutinib versus
temsirolimus (30.3 vs. 23.5 months; HR 0.74 [95% CI
0.54–1.02], P= 0.0621). In the initial analysis, number of
previous lines of therapy was identified as a prognostic factor
[5]. With longer follow-up this was evident, with patients
who had received 1 prior line of therapy benefiting the most
from the use of ibrutinib. More patients were able to achieve
a CR (33 vs. 16%), and those achieving a PR had a longer
DOR (22.3 vs. 10.0 months) when using ibrutinib after 1
versus >1 prior line of therapy. In ibrutinib patients with 1
prior line of therapy, this resulted in a doubling of PFS versus
ibrutinib patients with >1 prior line of therapy (25.4 vs.
12.1 months) and an almost 15-month improvement of OS
versus temsirolimus patients with 1 prior line of therapy (42.1
vs. 27.0 months). These data from the RAY study, irre-
spective of the number of prior lines of therapy, compare
favorably to the results from pivotal clinical trials of other
single agents in R/R MCL (e.g., bortezomib, lenalidomide,
and temsirolimus), the use of which was associated with
median PFS of 4–5 months, median OS of 13–19 months,
and ORRs of 22–33% [6–9]. Given that these findings sup-
port earlier use of ibrutinib in the relapsed/refractory setting,
a relevant clinical question is whether patients can be
successfully treated after progression on ibrutinib. Here, we
show that patients could be successfully rescued post ibru-
tinib therapy with rituximab-based chemotherapy (ORR=
41%), including bendamustine-rituximab (ORR= 53%).
Importantly, longer follow-up revealed no new late or
cumulative toxicities, supporting the overall well-tolerated
safety profile for ibrutinib [5]. The significant improvements
in PFS2 provide further evidence that ibrutinib benefit is
maintained beyond subsequent lines of treatment. Collec-
tively, these results support the role of ibrutinib in the
treatment of previously treated MCL. Emerging data suggest
that ibrutinib may also have a role in treatment-naïve MCL
[10], with multiple phase 3 studies underway (e.g., ENRICH
[EudraCT 2015-000832-13], SHINE [NCT01776840], and
TRIANGLE [NCT02858258]).
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Despite the progress made in the past two decades,
multiple myeloma (MM) remains an incurable disease and
the prognosis of patients relapsing after first-generation
novel agents is extremely poor [1]. Pomalidomide
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